XTL Biopharmaceuticals Ltd.

TASE:XTLB Stock Report

Market Cap: ₪65.2m

XTL Biopharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Shlomo Shalev

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure4.6yrs
CEO ownership0.2%
Management average tenureno data
Board average tenure9.8yrs

Recent management updates

Recent updates

We're Interested To See How XTL Biopharmaceuticals (TLV:XTLB) Uses Its Cash Hoard To Grow

Jul 02
We're Interested To See How XTL Biopharmaceuticals (TLV:XTLB) Uses Its Cash Hoard To Grow

CEO

Shlomo Shalev (62 yo)

4.6yrs

Tenure

Mr. Shlomo Spokone Shalev serves as Chief Executive Officer at XTL Biopharmaceuticals Ltd. since May 19, 2020. He has been the Chairman of the board of directors at G.F.C Green Fields Capital Ltd.since 1...

Board Members

NamePositionTenureCompensationOwnership
Shlomo Shalev
CEO & Director10yrsno data0.24%
₪ 157.0k
Doron Turgeman
Non-Executive Chairman of the Board10yrsno data0.027%
₪ 17.7k
Lee Simon
Member of Clinical Advisory Boardno datano datano data
Daniel Wallace
Member of Clinical Advisory Boardno datano datano data
Jonathan Schapiro
Non-Executive Director10yrsno data0%
₪ 0
Dobroslav Melamed
Independent Non-Executive Director10yrsno data0%
₪ 0
Murray Urowitz
Member of Clinical Advisory Boardno datano datano data
Osnat Fain
Independent Non-Executive & External Director9.8yrsno data0%
₪ 0
David Isenberg
Member of Clinical Advisory Board9.3yrsno datano data
Robert Fox
Member of Clinical Advisory Board7.8yrsno datano data
Simon Bowman
Member of Clinical Advisory Board7.8yrsno datano data
Alexander Rabinovich
Non-Executive Director7.7yrsno datano data

9.8yrs

Average Tenure

58yo

Average Age

Experienced Board: XTLB's board of directors are considered experienced (9.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 16:35
End of Day Share Price 2024/12/19 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

XTL Biopharmaceuticals Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.